These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24372463)

  • 1. Adherence and health care costs with single-pill fixed-dose combinations in hypertension management.
    Hilleman DE
    J Manag Care Pharm; 2014 Jan; 20(1):93-100. PubMed ID: 24372463
    [No Abstract]   [Full Text] [Related]  

  • 2. Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan.
    Wang X; Chen H; Essien E; Wu J; Serna O; Paranjpe R; Abughosh S
    J Manag Care Spec Pharm; 2019 Jun; 25(6):678-686. PubMed ID: 31134857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence.
    Sherrill B; Halpern M; Khan S; Zhang J; Panjabi S
    J Clin Hypertens (Greenwich); 2011 Dec; 13(12):898-909. PubMed ID: 22142349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients.
    Panjabi S; Lacey M; Bancroft T; Cao F
    J Am Soc Hypertens; 2013; 7(1):46-60. PubMed ID: 23321404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care.
    Schäfer HH; Scheunert U
    Swiss Med Wkly; 2013; 143():w13854. PubMed ID: 24163048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Issues in blood pressure control and the potential role of single-pill combination therapies.
    Burnier M; Brown RE; Ong SH; Keskinaslan A; Khan ZM
    Int J Clin Pract; 2009 May; 63(5):790-8. PubMed ID: 19220523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive medication adherence and subsequent healthcare utilization and costs.
    Pittman DG; Tao Z; Chen W; Stettin GD
    Am J Manag Care; 2010 Aug; 16(8):568-76. PubMed ID: 20712390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan.
    Wang X; Chen H; E E; Wu J; Serna O; Paranjpe R; Abughosh S
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):829-836. PubMed ID: 32703040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How common is true resistant hypertension?
    Bunker J; Callister W; Chang CL; Sever PS
    J Hum Hypertens; 2011 Feb; 25(2):137-40. PubMed ID: 21124342
    [No Abstract]   [Full Text] [Related]  

  • 10. Fixed-dose triple-combination treatments in the management of hypertension.
    Ram CV
    Manag Care; 2013 Dec; 22(12):45-55. PubMed ID: 24555265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment.
    Costa FV
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):265-274. PubMed ID: 28695464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives.
    Yang W; Chang J; Kahler KH; Fellers T; Orloff J; Wu EQ; Bensimon AG
    Curr Med Res Opin; 2010 Sep; 26(9):2065-76. PubMed ID: 20629600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy.
    Dickson M; Plauschinat CA
    Am J Cardiovasc Drugs; 2008; 8(1):45-50. PubMed ID: 18303937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access to Antihypertensive Drugs in China.
    Bai G; Bennet C; Wang J; Anderson GF
    Circulation; 2018 Oct; 138(17):1777-1779. PubMed ID: 30354658
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
    Baser O; Andrews LM; Wang L; Xie L
    J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacoeconomic analysis of antihypertensive therapy: advantages of fixed combinations].
    Leonova MV; Erofeeva SB; Bykov AV; Belousov IuB
    Kardiologiia; 2008; 48(1):43-50. PubMed ID: 18260995
    [No Abstract]   [Full Text] [Related]  

  • 17. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*.
    Chapman RH; Ferrufino CP; Kowal SL; Classi P; Roberts CS
    Int J Clin Pract; 2010 Jan; 64(2):169-81. PubMed ID: 20089007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
    Caro JJ; Lee K
    Curr Hypertens Rep; 2002 Dec; 4(6):417-8. PubMed ID: 12419166
    [No Abstract]   [Full Text] [Related]  

  • 19. [Relationship of polymedication in controlling blood pressure: compliance, persistence, costs and incidence of new cardiovascular events].
    Sicras Mainar A; Muñoz Ortí G; Font Ramos B; Majós Oró N; Navarro Artieda R; Ibáñez Nolla J
    Med Clin (Barc); 2013 Jul; 141(2):53-61. PubMed ID: 22766057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment for antihypertensive drug intake in France in 2019 and adherence].
    Bouhanick B; Vaïsse B; Schavgoulidze A; Gandia P
    Presse Med; 2019 Dec; 48(12):1520-1526. PubMed ID: 31761608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.